Curative Effect of Neoadjuvant Chemotherapy with XELOX Regimen on Advanced Gastric Cancer
Objective To observe the curative effect of neoadjuvant chemotherapy with XELOX regimen(oxaliplatin and capecitabine)on advanced gastric cancer and its influences on levels of serum tumor supplied group of factors(TSGF),carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)and pepsinogen(PG).Methods A total of 80 patients with advanced gastric cancer in the hospital were enrolled.All underwent XELOX chemotherapy.Serum TSGF,CEA,CA19-9 and PG[PG Ⅰ,PG Ⅱ,PG Ⅰ to PG Ⅱ ratio(PGR)]before and after treatment were compared.The curative effect and adverse reactions were observed.Results The total response rate in the second course of chemotherapy(38.75％)was higher than that in the first course of chemotherapy(23.75％)(P＜0.05).In the first and second course of chemotherapy,the levels of serum TSGF,CEA and CA19-9 were lower than those before treatment(P＜0.05).The above indexes in the second course of chemotherapy were lower than those in the first course of chemotherapy(P＜0.05).In the first course of chemotherapy,PG Ⅰ and PGR were higher than those before treatment(P＜0.05).In the second course of chemotherapy,PG Ⅰ and PGR were higher than those in the first course of chemotherapy(P＜0.05).PG Ⅱ was lower than that before treatment and in the first course of chemotherapy(P＜0.05).The incidence of leukopenia reduction at grade Ⅰ(31.25％),nausea and vomiting at grade Ⅰ(33.75％),neurotoxicity at grade Ⅰ(35.00％)and hand-foot syndrome at grade Ⅰ(31.25％)was relatively higher,while incidence of adverse reactions at grade Ⅲ was relatively lower.There was no adverse reactions at grade Ⅳ.Conclusion With process of neoadjuvant chemotherapy with XELOX regimen,clinical curative effect of advanced gastric cancer is increased,which can effectively reduce levels of TSGF,CEA,CA19-9,and increase the level of PGI.The safety and patients tolerance are good.
万方数据
维普
